Anthropometric measurements of children with neurofibromatosis type I: impact of plexiform neurofibroma volume and treatment

被引:1
作者
Lemberg, Kathryn M. [1 ,2 ]
Gross, Andrea M. [2 ]
Sproule, Lauren M. [3 ]
Liewehr, David J. [4 ]
Dombi, Eva [2 ]
Baldwin, Andrea [5 ]
Steinberg, Seth M. [4 ]
Bornhorst, Miriam [6 ,7 ]
Lodish, Maya [8 ]
Blakeley, Jaishri O. [9 ]
Widemann, Brigitte C. [2 ]
机构
[1] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[2] Ctr Canc Res, Pediat Oncol Branch, Bethesda, MD 20892 USA
[3] McGill Univ, Montreal, PQ, Canada
[4] Ctr Canc Res, Biostat & Data Management Sect, Bethesda, MD USA
[5] Frederick Natl Lab Canc Res, Clin Res Directorate, Frederick, MD USA
[6] Childrens Natl Hosp, Gilbert Family Neurofibromatosis Inst, Washington, DC USA
[7] Ann & Robert H Lurie Childrens Hosp Chicago, Ctr Canc & Blood Disorders, Chicago, IL USA
[8] Univ Calif San Francisco, Div Pediat Endocrinol, San Francisco, CA USA
[9] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
GROWTH; PUBERTY; ADULTS; FAMILY; AGE;
D O I
10.1038/s41390-024-03474-z
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BACKGROUND: In children and adolescents/young adults (CAYA) with neurofibromatosis type I (NF1), associations between anthropometric measurements, plexiform neurofibroma (pNF) tumor volume (TV), and treatment history are unknown. METHODS: We retrospectively investigated anthropometrics in CAYA on the National Cancer Institute (NCI) NF1 Natural History Study who had pNF TV assessed by imaging (n = 106). We determined CDC height/weight percentiles and estimated Preece-Baines (PB) height growth curve parameters. We evaluated variables that could impact height/weight including: (1) pNF volume, (2) pNF directed therapy, and (3) serum IGF-1. RESULTS: 23% of males and 20% of females had height <5th percentile; 13% of males had weight <5th percentile. Estimated median final adult height for males was 171.6 cm (CDC 23rd percentile) and for females was 156.2 cm (CDC 14th percentile). Inverse associations between height and weight percentiles and pNF volume were observed (Spearman's r = -0.277, -0.216, respectively). Estimated median final height was not meaningfully affected by patients who received pNF-directed treatment with MEK inhibitor. 52% of low serum IGF-1 measurements were concurrent with a height percentile <5th. CONCLUSIONS: Greater than expected percentages of patients had height/weight <5th percentile, and median final adult heights were <CDC 25th percentile. pNF volume was inversely associated with height/weight percentiles.
引用
收藏
页码:1918 / 1928
页数:11
相关论文
共 31 条
  • [1] Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use
    Bettegowda, Chetan
    Upadhayaya, Meena
    Evans, Gareth
    Kim, AeRang
    Mathios, Dimitrios
    Hanemann, Clemens O.
    [J]. NEUROLOGY, 2021, 97 (07) : S91 - S98
  • [2] A Call for Discovery and Therapeutic Development for Cutaneous Neurofibromas
    Blakeley, Jaishri O.
    Le, Lu Q.
    Lee, Sang Y.
    Ly, Ina
    Rhodes, Steven D.
    Romo, Carlos G.
    Sarin, Kavita Y.
    Staedtke, Verena
    Steensma, Matthew R.
    Wolkenstein, Pierre
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (08) : 1351 - 1357
  • [3] Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila
    Botero, Valentina
    Stanhope, Bethany A.
    Brown, Elizabeth B.
    Grenci, Eliza C.
    Boto, Tamara
    Park, Scarlet J.
    King, Lanikea B.
    Murphy, Keith R.
    Colodner, Kenneth J.
    Walker, James A.
    Keene, Alex C.
    Ja, William W.
    Tomchik, Seth M.
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [4] Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: A longitudinal study
    Carmi, D
    Shohat, M
    Metzker, A
    Dickerman, Z
    [J]. PEDIATRICS, 1999, 103 (06) : 1257 - 1262
  • [5] Clementi M, 1999, AM J MED GENET, V87, P317, DOI 10.1002/(SICI)1096-8628(19991203)87:4<317::AID-AJMG7>3.0.CO
  • [6] 2-X
  • [7] Puberty and Plexiform Neurofibroma Tumor Growth in Patients with Neurofibromatosis Type I
    Dagalakis, Urania
    Lodish, Maya
    Dombi, Eva
    Sinaii, Ninet
    Sabo, Jessica
    Baldwin, Andrea
    Steinberg, Seth M.
    Stratakis, Constantine A.
    Widemann, Brigitte C.
    [J]. JOURNAL OF PEDIATRICS, 2014, 164 (03) : 620 - 624
  • [8] NF1 plexiform neurofibroma growth rate by volumetric MRI - Relationship to age and body weight
    Dombi, E.
    Solomon, J.
    Gillespie, A. J.
    Fox, E.
    Balis, F. M.
    Patronas, N.
    Korf, B. R.
    Babovic-Vuksanovic, D.
    Packer, R. J.
    Belasco, J.
    Goldman, S.
    Jakacki, R.
    Kieran, M.
    Steinberg, S. M.
    Widemann, B. C.
    [J]. NEUROLOGY, 2007, 68 (09) : 643 - 647
  • [9] Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas
    Dombi, Eva
    Baldwin, Andrea
    Marcus, Leigh J.
    Fisher, Michael J.
    Weiss, Brian
    Kim, AeRang
    Whitcomb, Patricia
    Martin, Staci
    Aschbacher-Smith, Lindsey E.
    Rizvi, Tilat A.
    Wu, Jianqiang
    Ershler, Rachel
    Wolters, Pamela
    Therrien, Janet
    Glod, John
    Belasco, Jean B.
    Schorry, Elizabeth
    Brofferio, Alessandra
    Starosta, Amy J.
    Gillespie, Andrea
    Doyle, Austin L.
    Ratner, Nancy
    Widemann, Brigitte C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (26) : 2550 - 2560
  • [10] Recommendations for imaging tumor response in neurofibromatosis clinical trials
    Dombi, Eva
    Ardern-Holmes, Simone L.
    Babovic-Vuksanovic, Dusica
    Barker, Fred G.
    Connor, Steve
    Evans, D. Gareth
    Fisher, Michael J.
    Goutagny, Stephane
    Harris, Gordon J.
    Jaramillo, Diego
    Karajannis, Matthias A.
    Korf, Bruce R.
    Mautner, Victor
    Plotkin, Scott R.
    Poussaint, Tina Y.
    Robertson, Kent
    Shih, Chie-Schin
    Widemann, Brigitte C.
    [J]. NEUROLOGY, 2013, 81 (21) : S33 - S40